{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:07:10Z","timestamp":1772759230356,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T00:00:00Z","timestamp":1361750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T00:00:00Z","timestamp":1361750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1038\/leu.2013.60","type":"journal-article","created":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T07:38:15Z","timestamp":1361777895000},"page":"1650-1658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cleavage of BCR\u2013ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR\u2013ABL leukemic cells"],"prefix":"10.1038","volume":"27","author":[{"given":"J E","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B-R","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K P","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y-H","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D-W","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D-E","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,25]]},"reference":[{"key":"BFleu201360_CR1","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D . Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 1990; 247: 824\u2013830.","journal-title":"Science"},{"key":"BFleu201360_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1056\/NEJM199907153410306","volume":"341","author":"S Faderl","year":"1999","unstructured":"Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164\u2013172.","journal-title":"N Engl J Med"},{"key":"BFleu201360_CR3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD . Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290\u2013293.","journal-title":"Nature"},{"key":"BFleu201360_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","volume":"36","author":"J Groffen","year":"1984","unstructured":"Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G . Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93\u201399.","journal-title":"Cell"},{"key":"BFleu201360_CR5","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1365-2141.1995.tb08362.x","volume":"89","author":"P Shepherd","year":"1995","unstructured":"Shepherd P, Suffolk R, Halsey J, Allan N . Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol 1995; 89: 546\u2013554.","journal-title":"Br J Haematol"},{"key":"BFleu201360_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMra020777","volume":"349","author":"JM Goldman","year":"2003","unstructured":"Goldman JM, Melo JV . Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451\u20131464.","journal-title":"N Engl J Med"},{"key":"BFleu201360_CR7","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1038\/sj.onc.1201400","volume":"15","author":"D Cortez","year":"1997","unstructured":"Cortez D, Reuther G, Pendergast AM . The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 1997; 15: 2333\u20132342.","journal-title":"Oncogene"},{"key":"BFleu201360_CR8","doi-asserted-by":"publisher","first-page":"39223","DOI":"10.1074\/jbc.M007291200","volume":"275","author":"F Gesbert","year":"2000","unstructured":"Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD . BCR\/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase\/AKT pathway. J Biol Chem 2000; 275: 39223\u201339230.","journal-title":"J Biol Chem"},{"key":"BFleu201360_CR9","first-page":"5126","volume":"63","author":"R Nimmanapalli","year":"2003","unstructured":"Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003; 63: 5126\u20135135.","journal-title":"Cancer Res"},{"key":"BFleu201360_CR10","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1182\/blood.V91.7.2415","volume":"91","author":"L Dubrez","year":"1998","unstructured":"Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E . BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 1998; 91: 2415\u20132422.","journal-title":"Blood"},{"key":"BFleu201360_CR11","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","volume":"29","author":"M Steinberg","year":"2007","unstructured":"Steinberg M . Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007; 29: 2289\u20132308.","journal-title":"Clin Ther"},{"key":"BFleu201360_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031\u20131037.","journal-title":"N Engl J Med"},{"key":"BFleu201360_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1365-2141.2002.03899.x","volume":"119","author":"AS Tsao","year":"2002","unstructured":"Tsao AS, Kantarijian H, Talpaz M . STI-571 in chronic myelogenous leukaemia. Br J Haematol 2002; 119: 15\u201324.","journal-title":"Br J Haematol"},{"key":"BFleu201360_CR14","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","volume":"108","author":"HA Bradeen","year":"2006","unstructured":"Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108: 2332\u20132338.","journal-title":"Blood"},{"key":"BFleu201360_CR15","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876\u2013880.","journal-title":"Science"},{"key":"BFleu201360_CR16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28\u201337.","journal-title":"Blood"},{"key":"BFleu201360_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","volume":"359","author":"N von Bubnoff","year":"2002","unstructured":"von Bubnoff N, Schneller F, Peschel C, Duyster J . BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487\u2013491.","journal-title":"Lancet"},{"key":"BFleu201360_CR18","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531\u20132541.","journal-title":"N Engl J Med"},{"key":"BFleu201360_CR19","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O'Hare","year":"2007","unstructured":"O'Hare T, Eide CA, Deininger MW . Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242\u20132249.","journal-title":"Blood"},{"key":"BFleu201360_CR20","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1073\/pnas.94.9.4262","volume":"94","author":"SW Santoro","year":"1997","unstructured":"Santoro SW, Joyce GF . A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997; 94: 4262\u20134266.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201360_CR21","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1089\/10430349950016573","volume":"10","author":"Y Wu","year":"1999","unstructured":"Wu Y, Yu L, McMahon R, Rossi JJ, Forman SJ, Snyder DS . Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum Gene Ther 1999; 10: 2847\u20132857.","journal-title":"Hum Gene Ther"},{"key":"BFleu201360_CR22","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1093\/nar\/25.15.3074","volume":"25","author":"T Kuwabara","year":"1997","unstructured":"Kuwabara T, Warashina M, Tanabe T, Tani K, Asano S, Taira K . Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. Nucleic Acids Res 1997; 25: 3074\u20133081.","journal-title":"Nucleic Acids Res"},{"key":"BFleu201360_CR23","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V92.11.4336","volume":"92","author":"A Maran","year":"1998","unstructured":"Maran A, Waller CF, Paranjape JM, Li G, Xiao W, Zhang K et al. 2',5'-Oligoadenylate-antisense chimeras cause RNase L to selectively degrade bcr\/abl mRNA in chronic myelogenous leukemia cells. Blood 1998; 92: 4336\u20134343.","journal-title":"Blood"},{"key":"BFleu201360_CR24","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1182\/blood.V91.9.3414","volume":"91","author":"R Bhatia","year":"1998","unstructured":"Bhatia R, Verfaillie CM . Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood 1998; 91: 3414\u20133422.","journal-title":"Blood"},{"key":"BFleu201360_CR25","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1182\/blood-2002-12-3899","volume":"102","author":"L Wohlbold","year":"2003","unstructured":"Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J et al. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 2003; 102: 2236\u20132239.","journal-title":"Blood"},{"key":"BFleu201360_CR26","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1182\/blood-2002-06-1685","volume":"101","author":"M Scherr","year":"2003","unstructured":"Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M . Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 2003; 101: 1566\u20131569.","journal-title":"Blood"},{"key":"BFleu201360_CR27","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1093\/nar\/gkf451","volume":"30","author":"V Rapozzi","year":"2002","unstructured":"Rapozzi V, Burm BE, Cogoi S, van der Marel GA, van Boom JH, Quadrifoglio F et al. Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids. Nucleic Acids Res 2002; 30: 3712\u20133721.","journal-title":"Nucleic Acids Res"},{"key":"BFleu201360_CR28","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1158\/1535-7163.MCT-06-0006","volume":"5","author":"V Rapozzi","year":"2006","unstructured":"Rapozzi V, Cogoi S, Xodo LE . Antisense locked nucleic acids efficiently suppress BCR\/ABL and induce cell growth decline and apoptosis in leukemic cells. Mol Cancer Ther 2006; 5: 1683\u20131692.","journal-title":"Mol Cancer Ther"},{"key":"BFleu201360_CR29","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.bbrc.2007.12.020","volume":"366","author":"KJ Jang","year":"2008","unstructured":"Jang KJ, Lee NR, Yeo WS, Jeong YJ, Kim DE . Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase\/Helicase. Biochem Biophys Res Commun 2008; 366: 738\u2013744.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu201360_CR30","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.chembiol.2004.08.021","volume":"11","author":"DE Kim","year":"2004","unstructured":"Kim DE, Joyce GF . Cross-catalytic replication of an RNA ligase ribozyme. Chem Biol 2004; 11: 1505\u20131512.","journal-title":"Chem Biol"},{"key":"BFleu201360_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/oli.2010.0256","volume":"20","author":"B Lee","year":"2010","unstructured":"Lee B, Kim KB, Oh S, Choi JS, Park JS, Min DH et al. Suppression of hepatitis C virus genome replication in cells with RNA-cleaving DNA enzymes and short-hairpin RNA. Oligonucleotides 2010; 20: 285\u2013296.","journal-title":"Oligonucleotides"},{"key":"BFleu201360_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1006\/jmbi.1996.0345","volume":"259","author":"R Kronenwett","year":"1996","unstructured":"Kronenwett R, Haas R, Sczakiel G . Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes. J Mol Biol 1996; 259: 632\u2013644.","journal-title":"J Mol Biol"},{"key":"BFleu201360_CR33","first-page":"137","volume":"5","author":"BB Patel","year":"2008","unstructured":"Patel BB, He YA, Li XM, Frolov A, Vanderveer L, Slater C et al. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics 2008; 5: 137\u2013149.","journal-title":"Cancer Genomics Proteomics"},{"key":"BFleu201360_CR34","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","volume":"103","author":"S Chu","year":"2004","unstructured":"Chu S, Holtz M, Gupta M, Bhatia R . BCR\/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Blood 2004; 103: 3167\u20133174.","journal-title":"Blood"},{"key":"BFleu201360_CR35","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1158\/1535-7163.MCT-09-1001","volume":"9","author":"Y Xu","year":"2010","unstructured":"Xu Y, Fang F, Sun Y, Clair DK, Clair WH . RelB-dependent differential radiosensitization effect of STI571 on prostate cancer cells. Mol Cancer Ther 2010; 9: 803\u2013812.","journal-title":"Mol Cancer Ther"},{"key":"BFleu201360_CR36","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1158\/1078-0432.CCR-0754-03","volume":"10","author":"D Matei","year":"2004","unstructured":"Matei D, Chang DD, Jeng MH . Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation. Clin Cancer Res 2004; 10: 681\u2013690.","journal-title":"Clin Cancer Res"},{"key":"BFleu201360_CR37","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1038\/sj.onc.1205724","volume":"21","author":"A Klejman","year":"2002","unstructured":"Klejman A, Rushen L, Morrione A, Slupianek A, Skorski T . Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571. Oncogene 2002; 21: 5868\u20135876.","journal-title":"Oncogene"},{"key":"BFleu201360_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrclinonc.2009.112","volume":"6","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J . Imatinib and beyond--exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009; 6: 535\u2013543.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFleu201360_CR39","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","volume":"47","author":"P La Rosee","year":"2010","unstructured":"La Rosee P, Deininger MW . Resistance to imatinib: mutations and beyond. Semin Hematol 2010; 47: 335\u2013343.","journal-title":"Semin Hematol"},{"key":"BFleu201360_CR40","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3324\/haematol.2009.016063","volume":"95","author":"M Koldehoff","year":"2010","unstructured":"Koldehoff M, Kordelas L, Beelen DW, Elmaagacli AH . Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. Haematologica 2010; 95: 388\u2013397.","journal-title":"Haematologica"},{"key":"BFleu201360_CR41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/sj.leu.2403999","volume":"20","author":"J Rangatia","year":"2006","unstructured":"Rangatia J, Bonnet D . Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation. Leukemia 2006; 20: 68\u201376.","journal-title":"Leukemia"},{"key":"BFleu201360_CR42","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/sj.cdd.4401210","volume":"10","author":"AE Bueno-da-Silva","year":"2003","unstructured":"Bueno-da-Silva AE, Brumatti G, Russo FO, Green DR, Amarante-Mendes GP . Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death Differ 2003; 10: 592\u2013598.","journal-title":"Cell Death Differ"},{"key":"BFleu201360_CR43","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.leukres.2003.10.022","volume":"28","author":"T Kawano","year":"2004","unstructured":"Kawano T, Horiguchi-Yamada J, Saito S, Iwase S, Furukawa Y, Kano Y et al. Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells. Leuk Res 2004; 28: 623\u2013629.","journal-title":"Leuk Res"},{"key":"BFleu201360_CR44","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1007\/s00018-008-8029-y","volume":"65","author":"DA Baum","year":"2008","unstructured":"Baum DA, Silverman SK . Deoxyribozymes: useful DNA catalysts in vitro and in vivo. Cell Mol Life Sci 2008; 65: 2156\u20132174.","journal-title":"Cell Mol Life Sci"},{"key":"BFleu201360_CR45","doi-asserted-by":"publisher","first-page":"641","DOI":"10.4161\/cbt.3.7.918","volume":"3","author":"SH Pun","year":"2004","unstructured":"Pun SH, Tack F, Bellocq NC, Cheng J, Grubbs BH, Jensen GS et al. Targeted delivery of RNA-cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol Ther 2004; 3: 641\u2013650.","journal-title":"Cancer Biol Ther"},{"key":"BFleu201360_CR46","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1016\/j.biomaterials.2011.12.015","volume":"33","author":"SR Ryoo","year":"2012","unstructured":"Ryoo SR, Jang H, Kim KS, Lee B, Kim KB, Kim YK et al. Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown. Biomaterials 2012; 33: 2754\u20132761.","journal-title":"Biomaterials"},{"key":"BFleu201360_CR47","doi-asserted-by":"publisher","first-page":"H2240","DOI":"10.1152\/ajpheart.00350.2003","volume":"285","author":"EA Nunamaker","year":"2003","unstructured":"Nunamaker EA, Zhang HY, Shirasawa Y, Benoit JN, Dean DA . Electroporation-mediated delivery of catalytic oligodeoxynucleotides for manipulation of vascular gene expression. Am J Physiol Heart Circ Physiol 2003; 285: H2240\u2013H2247.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFleu201360_CR48","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev.bi.62.070193.001203","volume":"62","author":"RA Morgan","year":"1993","unstructured":"Morgan RA, Anderson WF . Human gene therapy. Annu Rev Biochem 1993; 62: 191\u2013217.","journal-title":"Annu Rev Biochem"},{"key":"BFleu201360_CR49","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1023\/A:1016026831789","volume":"15","author":"RD Grubbs","year":"2002","unstructured":"Grubbs RD . Intracellular magnesium and magnesium buffering. Biometals 2002; 15: 251\u2013259.","journal-title":"Biometals"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201360","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:36:17Z","timestamp":1648744577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,25]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["BFleu201360"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.60","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,25]]},"assertion":[{"value":"18 June 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}